News
At the 2025 ASCO annual meeting, Dr. Hoffman-Censits reported an interim analysis of JAVELIN Bladder Medley assessing avelumab + sacituzumab govitecan versus avelumab monotherapy. Notably, this trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback